Compile Data Set for Download or QSAR
Report error Found 83 Enz. Inhib. hit(s) with all data for entry = 11566
TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627350(US20230331675, Compound 6 | (S,E)-1-(2-Methoxy-4-(...)
Affinity DataIC50: 0.590nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627412((S,E)-1-(4-(2-(2-Chloro-[1,1'-biphenyl]-3-yl)vinyl...)
Affinity DataIC50: 0.680nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627350(US20230331675, Compound 6 | (S,E)-1-(2-Methoxy-4-(...)
Affinity DataIC50: 0.730nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627350(US20230331675, Compound 6 | (S,E)-1-(2-Methoxy-4-(...)
Affinity DataIC50: 1.60nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627352((S,E)-1-(5-Chloro-4-(2-(2-cyano-[1,1'-biphenyl]-3-...)
Affinity DataIC50: 1.60nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627422((S,E)-1-(2-((5-Iodopyridin-3-yl)methoxy)-4-(2-(2-m...)
Affinity DataIC50: 1.85nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627351((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 1.90nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627350(US20230331675, Compound 6 | (S,E)-1-(2-Methoxy-4-(...)
Affinity DataIC50: 2nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627359((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 2.10nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627421((S,E)-1-(2-((2-Iodopyridin-4-yl)methoxy)-4-(2-(2-m...)
Affinity DataIC50: 2.13nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627387((S,E)-1-(2-Methoxy-4-(2-(2-methyl-d3)-[1,1'-biphen...)
Affinity DataIC50: 2.20nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627428((S,E)-1-(2-(2-Fluoroethoxy)-4-(2-(2-methyl-[1,1'-b...)
Affinity DataIC50: 2.80nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627356((S,E)-2-((4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl...)
Affinity DataIC50: 3.40nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627427((S,E)-1-(2-(3-Fluoropropoxy)-4-(2-(2-methyl-[1,1'-...)
Affinity DataIC50: 3.58nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627364((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 3.70nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627420((S,E)-1-(2-((4-Iodopyridin-2-yl)methoxy)-4-(2-(2-m...)
Affinity DataIC50: 3.97nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627414((S,E)-1-(4-(2-(2-Fluoromethyl-[1,1'-biphenyl]-3-yl...)
Affinity DataIC50: 3.99nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627354((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 4.20nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627426((S,E)-1-(2-(4-Fluorobutoxy)-4-(2-(2-methyl-[1,1'-b...)
Affinity DataIC50: 4.34nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627361((S,E)-4-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 4.40nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627390((S,E)-1-(5-Chloro-4-(2-(2-cyano-[1,1'-biphenyl]-3-...)
Affinity DataIC50: 4.40nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627370((S,E)-4-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 4.70nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627419((S,E)-1-(2-((4-Iodo-pyridin-2-yl)methoxy)-5-methyl...)
Affinity DataIC50: 5.31nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627417((S,E)-1-(2-((3-Iodobenzyloxy)-4-(2-(2-methyl-[1,1'...)
Affinity DataIC50: 5.91nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627363((E)-(5-Chloro-4-(2-(2-cyano-[1,1'-biphenyl]-3-yl)v...)
Affinity DataIC50: 6.20nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627349((S,E)-1-(5-Chloro-2-methyl-4-(2-(2-methyl-[1,1'-bi...)
Affinity DataIC50: 6.5nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627391(US20230331675, Compound 58 | US20230331675, Compou...)
Affinity DataIC50: 6.80nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627368((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 6.80nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627423((S,E)-1-(2-(4-Fluorobutoxy)-5-methyl-4-(2-(2-methy...)
Affinity DataIC50: 6.99nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627415((E)-2-((4-(2-(2-Fluoromethyl-[1,1'-biphenyl]-3-yl)...)
Affinity DataIC50: 7.09nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627403((R,E)-1-(2-Methoxy-4-(2-(2-methyl-[1,1'-biphenyl]-...)
Affinity DataIC50: 7.42nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627374((S,E)-4-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 7.70nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627384((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 8nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627424((S,E)-1-(2-(3-Fluoropropoxy)-5-methyl-4-(2-(2-meth...)
Affinity DataIC50: 8.03nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627391(US20230331675, Compound 58 | US20230331675, Compou...)
Affinity DataIC50: 8.90nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627369((S,E)-4-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 9.10nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627411((S,E)-1-(2-Methoxy-5-methyl-4-(2-(2-methyl-[1,1'-b...)
Affinity DataIC50: 9.31nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627355((S,E)-4-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 10.1nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627345((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 10.2nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627348((S,E)-1-(4-(2-(2-Methyl-[1,1'-biphenyl]-3-yl)vinyl...)
Affinity DataIC50: 10.7nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627366((S,E)-4-(5-Chloro-2-methyl-4-(2-(2-methyl-[1,1'-bi...)
Affinity DataIC50: 11.4nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627408((S,Z)-1-(4-(1-Bromo-2-(2-methyl-[1,1'-biphenyl]-3-...)
Affinity DataIC50: 12.8nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627360((E)-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)-2-(...)
Affinity DataIC50: 14.5nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627385((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 18.6nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627362((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 22.2nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627353((S,E)-4-(5-Chloro-4-(2-(2-cyano-[1,1'-biphenyl]-3-...)
Affinity DataIC50: 25.8nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627346((S,E)-1-(3-Chloro-4-(2-(2-cyano-[1,1'-biphenyl]-3-...)
Affinity DataIC50: 26.3nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627416((S,E)-1-(2-((3-Iodobenzyloxy)-5-methyl-4-(2-(2-met...)
Affinity DataIC50: 28.4nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560589(US11384048, Compound 29 | US20230331675, Compound ...)
Affinity DataIC50: 29.5nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627405((S,Z)-1-(4-(1-Fluoro-2-(2-methyl-[1,1'-biphenyl]-3...)
Affinity DataIC50: 29.5nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 83 total ) | Next | Last >>
Jump to: